Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.18 -0.68 (-0.68%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
95 96 Next >
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
3 Biotech Stocks to Buy in Case of Another Pandemic
These are three of the best biotech stocks to keep an eye on as the industry helps governments prepare for the next pandemic. 
Via InvestorPlace
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
From Merck & Co., Inc.
Via Business Wire
Forget Nvidia: Billionaires Are Dumping It and Piling Into These 3 Surprising Value Stocks Instead
Nvidia's three most-prominent billionaire sellers opted to put their respective fund's capital to work in a trio of brand-name companies trading at a discount. 
Via The Motley Fool
Merck's Acquisition of EyeBio Finalized
Merk announced the acquisition of EyeBio, introducing a novel candidate to the company's pipeline, Restoret. 
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
Via Benzinga
Merck & Co Unusual Options Activity
Via Benzinga
Insights Into Merck &amp; Co's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer... 
Via Benzinga
Merck Completes Acquisition of EyeBio
From Merck & Co., Inc.
Via Business Wire
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
These are the healthcare stocks to buy as they represent companies with good fundamentals, stable growth visibility and cash flow upside. 
Via InvestorPlace
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Q2 estimates have been stable heading into earnings season, potentially setting a lower bar for corporations to beat analyst expectations and surprise to the upside. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Merck Animal Health announced the purchase of Elanco Animal Health's aquaculture business.Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture bus 
Via Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
Uncover top picks in undervalued blue-chip stocks, unfairly punished yet consistently delivering strong operational results 
Via InvestorPlace
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung... 
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
These are the blue-chip stocks to buy as they represent fundamentally strong companies with robust free cash flow visibility 
Via InvestorPlace
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... 
Via Benzinga
Exposures COVID-19
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Ten of the Dow Jones Industrial Average stocks were up double digit percentage in the first half of 2024. A look at the best and worst performers. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Merck Stock On Monday?
Merck secures exclusive global rights to develop and commercialize opevesostat (MK-5684/ODM-208) for hormone-dependent cancers. Orion is eligible for milestone payments up to $1.63 billion and tiered... 
Via Benzinga
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback